Cytokinetics, Incorporated
CYTK
Rang in aandelen
#2301
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Aandeelprijs
$62.31
Laatst gesynchroniseerd: 2026-10-16
Marktkapitalisatie
$8.66B
Verandering (1 dag)
-2.51%
Verandering (1 jaar)
6.63%
Land
US
Handel Cytokinetics, Incorporated (CYTK)
Categorie
Healthcare
Operationele marge voor Cytokinetics, Incorporated (CYTK)
Operationele marge op October 2026 TTM: -992.98%
Volgens de meest recente financiële rapporten en aandelenkoers van Cytokinetics, Incorporated is de huidige operationele marge (TTM) -992.98%. Eind 2023 had het bedrijf een operationele marge van -6,589.71%.
Geschiedenis van de operationele marge van Cytokinetics, Incorporated van 2000 tot 2026
Operationele marge aan het einde van elk jaar
| Jaar | Operationele Marge | Wijzigen |
|---|---|---|
| 2026 (TTM) | -992.98% | -65.79% |
| 2024 | -2,902.72% | -55.95% |
| 2023 | -6,589.71% | 1,822.60% |
| 2022 | -342.75% | 29.56% |
| 2021 | -264.54% | 57.21% |
| 2020 | -168.27% | -54.27% |
| 2019 | -367.97% | 30.37% |
| 2018 | -282.26% | -66.72% |
| 2017 | -848.26% | -4,930.64% |
| 2016 | 17.56% | -113.45% |
| 2015 | -130.53% | 315.30% |
| 2014 | -31.43% | -71.58% |
| 2013 | -110.59% | -78.62% |
| 2012 | -517.29% | -56.86% |
| 2011 | -1,199.10% | -37.74% |
| 2010 | -1,926.08% | -6,119.00% |
| 2009 | 32.00% | -106.73% |
| 2008 | -475.68% | 14.71% |
| 2007 | -414.67% | -78.86% |
| 2006 | -1,961.56% | 291.67% |
| 2005 | -500.82% | 75.16% |
| 2004 | -285.92% | -7.20% |
| 2003 | -308.12% | 46.42% |
| 2002 | -210.43% | -3.14% |
| 2001 | -217.25% | 0.00% |
| 2000 | 0.00% | 0.00% |
Operationele marge van vergelijkbare bedrijven of concurrenten
| Bedrijf | Operationele Marge | Verschil in operationele marge | Land |
|---|---|---|---|
| 38.59% | -100.04% |
US
|
|
| -149.01% | -99.85% |
US
|
|
| 25.57% | -100.03% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.03% |
NL
|
Wat is de Operationele marge van een bedrijf?
De Operationele marge is een belangrijke indicator om de winstgevendheid van een bedrijf te beoordelen. Hogere operationele marges zijn over het algemeen beter omdat ze aangeven dat een bedrijf zijn producten of diensten veel duurder kan verkopen dan de productiekosten. De Operationele marge wordt berekend door de winst van een bedrijf te delen door de omzet.